On September 17th, OBIO held a dinner to bring together CAAP and CAAP Alumni companies. OBIO would like to thank everyone who came out and joined us to discuss common experiences, challenges and what's coming next.
On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.
Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.
This week, the Globe & Mail reported that venture-capital investment surged to its strongest first half on record, injecting $2.15-billion into Canadian startups and scale-ups, according to the Canadian Venture Capital & Private Equity Association (CVCA).